Effects of Darkness Retreat: a Pilot Study
Effect of Darkness Retreat on Worry and Rumination in a Non-clinical Population: a Pilot Study
University of Social Sciences and Humanities, Warsaw
30 participants
Oct 16, 2025
INTERVENTIONAL
Conditions
Summary
The primary goal of this pilot study is to test the feasibility and safety of a research protocol for a voluntary darkness retreat. The study will also allow for a preliminary examination of the psychological effects of the retreat. The investigators will investigate whether participants experience changes in their well-being and ruminative style, whether these changes persist over time, and if these effects are moderated by individual characteristics such as readiness for change or subjective evaluation of the experience as well as frequency of participants' monitoring. Participants will be randomly assigned to one of two experimental groups, both of which will spend 3 days and 3 nights in seclusion. These groups will differ only in the frequency of psychological monitoring during the retreat, allowing us to compare the effectiveness and safety of each protocol.
Eligibility
Inclusion Criteria14
- Participants will be recruited from university/postgraduate students through a two-stage process.
- Stage I. Individuals expressing interest in participation will be asked to confirm that they are not currently engaged in psychotherapy or coaching, are not taking psychotropic medication, and are in generally good physical health. The following individuals will be excluded from the study: those diagnosed with an acute or chronic somatic illness (e.g., cardiovascular disease); psychiatric or neurological disorders (e.g., depression, addiction, bipolar disorder, schizophrenia, epilepsy, stroke, severe brain injury, Parkinson's disease, Alzheimer's disease or other forms of dementia); those exhibiting active suicidal tendencies with a plan or intent; those taking psychotropic medication; engaged in psychotherapy or coaching; and pregnant individuals.
- Preliminary verification of these criteria will be carried out using a screening questionnaire containing demographic questions and items regarding psychotherapy/coaching, use of psychoactive medication, somatic health, suicidal tendencies, pregnancy, and confirmation of a history of diagnoses in the categories of psychotic disorders, eating disorders, obsessive-compulsive disorder, substance use disorders, bipolar disorder, along with the following questionnaires:
- Participants must obtain a total score between 40 and 80. (40-59 = moderate level of worry/anxiety) (60-80 = high level of worry/anxiety)
- In cases where participants fall within the high range, if clinical levels of worry are identified during the clinical interview, they will be excluded from participation.
- PAtient Health Questionnaire-9 (PHQ-9, range 0-27, higher scores indicating worse functioning): Individuals scoring above 10 will be considered at elevated risk for depression, and those scoring 20 or higher will not be invited to the clinical interview.
- Generalized Anxiety Disorder-7 (GAD-7, range 0-21, higher scores indicating worse functioning): Individuals scoring 7 or higher will be classified as having elevated generalized anxiety symptoms, and those scoring 15 or higher will be excluded from further participation.
- Alcohol Use Disorders Identification Test (AUDIT, range 0-40, higher scores indicating worse functioning): Individuals scoring above 8 will be considered at elevated risk for problematic drinking, and those scoring 22 or higher will not be invited to the clinical interview.
- Drug Use Disorders Identification Test (DUDIT, range 0-44, higher scores indicating worse functioning): Individuals scoring above 4 will be classified as at elevated risk for substance use, and those scoring 7 or higher will be excluded.
- The questionnaire will also include the following measures, which will not be used for automatic exclusion but will indicate the need for further evaluation during the clinical interview if the following thresholds are met:
- DSM-5 - Panic Disorder (range 0-40, higher scores indicating worse functioning): score ≥ 26 DSM-5 - Social Anxiety Disorder (range 0-40, higher scores indicating worse functioning): score ≥ 26 DSM-5 - Post-Traumatic Stress Disorder (range 0-44, higher scores indicating worse functioning): score \> 22
- Only individuals who are not excluded based on the above criteria will be invited to the next stage.
- Stage II. Candidates meeting the preliminary criteria will be invited to an online clinical interview with a psychologist. Approximately one week before the scheduled interview, participants will receive via email a link to the Personality Beliefs Questionnaire (PBQ; Zawadzki et al., 2017), that would help in a more in-depth assessment of psychological functioning during the actual meeting. In order to exclude clinical cases, the psychologist will use the structured clinical interview M.I.N.I. (Mini International Neuropsychiatric Interview)
- Participants who complete the psychological interview-regardless of their final qualification for the study-will receive a compensation of approximately 200 ZŁ in shopping vouchers (50EUR).
Interventions
The intervention is a voluntary darkness retreat involving three days and three nights of continuous seclusion in a completely dark cabin, with no access to external light sources or electronic devices. During the retreat, participants are consulted about their well-being through a standardized interview protocol, with consultation frequency determined by their assigned group. Participants in both groups will be equipped with WHOOP wristbands - devices monitoring physiological activity. These wristbands will serve a dual purpose: From a research perspective, they will provide access to biological data- circadian rhythm patterns and heart rate variability, offering deeper insights into the physiological processes accompanying the darkness retreat experience. From a safety perspective, they will enable real-time monitoring of participants' condition, supporting one of the main goals of the pilot study: ensuring participant safety while assessing the feasibility of the procedure.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07429617